Researchers at Munich's Leibniz Institute for Food Systems Biology have discovered a troubling gap in the standard tests used to certify barley beer as gluten-free: the antibody-based methods do not detect all the celiac-triggering peptides that lurk in some products officially labeled safe. The finding reveals a fundamental mismatch between how we test for gluten and what we're actually looking for—a gap that could matter enormously for the millions of people with celiac disease who depend on these certifications to eat without fear.
In the European Union and under international guidelines, a food is considered gluten-free if it contains no more than 20 milligrams of gluten per kilogram—a threshold designed to allow most people with celiac disease to tolerate the product safely. Barley naturally contains gluten, so breweries use enzymatic processes to reduce it, then verify their work using standardized tests, typically enzyme-linked immunosorbent assays known as ELISA. These tests use antibodies to detect gluten residues and the protein fragments, or peptides, produced during gluten breakdown. It sounds straightforward. But it isn't.
A team led by principal investigator Katharina Scherf and first author Eleonora Tissen examined four conventional barley beers and 21 labeled gluten-free, comparing two established ELISA methods with a newly developed technique called nano-liquid chromatography-tandem mass spectrometry. The differences in their results were striking. The G12-ELISA test confirmed that all 21 gluten-free beers met the 20-milligram threshold. But the R5-ELISA detected gluten concentrations exceeding the EU limit in four of those same beers—a fundamental discrepancy that reveals the tests are not equivalent. More revealing still, the mass spectrometry method identified 44 peptides known from scientific literature to trigger celiac disease, with 29 of these found in beers labeled gluten-free. Seventeen of those 44 celiac-active peptides had structures that current ELISA antibodies simply cannot detect.
The reason lies in how these antibody tests work. Conventional ELISA tests use monoclonal antibodies that recognize only short, specific protein sequences called epitopes. But celiac disease can be triggered by peptides with different epitope structures—structures the current antibodies miss entirely. "Our results mean that gluten-free barley beers are generally safe," Tissen explained. "However, they also show that there can be discrepancies between antibody tests and that they do not detect all celiac-active peptides known from the literature."
The good news, Scherf emphasizes, is that the additional celiac-active peptides her team found were present in very low concentrations, below the EU limit. But the team stresses that further investigation is essential to determine whether these peptides actually trigger health-relevant reactions in people with celiac disease. The uncertainty matters: celiac disease is a chronic autoimmune disorder of the small intestine, and for those living with it, even small oversights in food safety testing can have serious consequences.
Scherf sees the path forward clearly: "In the long term, the combination of established rapid tests and modern mass spectrometry methods could make gluten-free foods even safer." The study, published in Applied Food Research, provides a roadmap for how better analytical methods could reshape food safety standards—not just for beer, but for all gluten-free products. The precision of mass spectrometry offers a way to detect what conventional tests miss, bringing the promise of genuinely comprehensive protection for people whose health depends on it.